Therefore, combining fibroblast targeted therapy with currently available biological therapeutic agents such as tumor necrosis factor inhibitors can be a viable therapeutic strategy to achieve a long-term remission with little or no more increased risk in causing serious adverse effects such as infections in patients with RA. Here, TNF is linked to infection.